Placebo to MK-0616 - Tablet
Sponsors
Merck Sharp & Dohme LLC
Conditions
ASCVD - Atherosclerotic Cardiovascular DiseaseHeterozygous Familial Hypercholesterolemia (HeFH)
Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Heterozygous Familial Hypercholesterolemia
CompletedCTIS2022-502782-14-00
Start: 2023-09-28End: 2025-04-02Target: 123Updated: 2025-02-20
A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk
WithdrawnCTIS2022-502781-24-00
Target: 350Updated: 2023-11-06
A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk
Active, not recruitingCTIS2022-502781-24-01
Start: 2024-06-05Target: 3535Updated: 2025-09-25